Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026)

Allogene Therapeutics has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $21.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $21.1 million, up 50.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.3 million (down 71.1% YoY), and the FY2025 annual result was $30.2 million, down 74.15% from the prior year.
• Cash from Financing Activities came in at $21.1 million for Q1 2026 at Allogene Therapeutics, up from $7.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q2 2024 to a low of $24000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $3.2 million (2025), against an average of $15.7 million.
• Across the five-year window, Cash from Financing Activities plunged 99.25% in 2022 and jumped 372916.67% in 2023, its largest moves.
• Allogene Therapeutics' Cash from Financing Activities stood at $46000.0 in 2022, then surged by 236.96% to $155000.0 in 2023, then jumped by 3605.16% to $5.7 million in 2024, then soared by 36.84% to $7.9 million in 2025, then surged by 168.76% to $21.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $21.1 million (Q1 2026), $7.9 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.